ReviewNature reviews. Drug discovery2026
The therapeutic potential of orphan adhesion G-protein-coupled receptors.
Review in Nature reviews. Drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic targeting of adhesion GPCRs: a status update and future potential.Expert opinion on drug discovery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adhesion G-protein-coupled receptors (aGPCRs) are essential membrane proteins that contribute to diverse human pathologies, including cancer, psychiatric disorders and autoimmune diseases. A defining feature of these receptors is the large N terminus including the GPCR autoproteolysis-inducing domain, which mediates autoproteolysis and enables complex modes of activation through both cis and trans signalling. Recent breakthroughs in structural biology, in particular, cryogenic electron microscopy structures of aGPCRs, have transformed our understanding of receptor activation and facilitated development of small-molecule agonists and antibody-based strategies, which hold considerable promise for therapeutic intervention. In this Review, we summarize the roles of aGPCRs in human disease and in phenotypes characterized in animal models. We consolidate current insights into aGPCR structure-function relationships, highlight how distinct activation mechanisms are already being harnessed to modulate receptor activity in vitro and in vivo, and discuss how these principles could be leveraged for future therapeutic targeting.
Indexed as
Identifiers
41748743What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.